Histopathology of Bone Marrow

Travlos, Gregory S.

doi:10.1080/01926230600964706

Cited by 98 publications

(99 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of specific stains in addition to hematoxylin and eosin is not essential to evaluate fibrosis in rat bone marrow because of the distinctive morphologic presentation. [24][25][26] …”

Section: Animal Studymentioning

confidence: 99%

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

Kuter

Mufti

Bain

et al. 2009

Blood

166

132

View full text Add to dashboard Cite

Romiplostim is a thrombopoietin receptor agonist that increases platelet counts in patients with chronic immune thrombocytopenia (ITP). Thrombopoietin receptor agonists are reported to increase the risk for reticulin fiber deposition within bone marrow. This report describes bone marrow findings from romiplostim-treated rats, a retrospective analysis of reticulin observed in romiplostim ITP clinical trials, and a prospective clinical study of the effects of romiplostim on bone marrow morphology. In rats, romiplostim produced a dose-dependent increase in bone marrow fibrosis that resolved after treatment withdrawal. Of 271 ITP patients in romiplostim clinical trials, 10 were reported to have reticulin deposition; reticulin grade was increased in 4 of 5 patients with both pretreatment and on-treatment bone marrow results. Reticulin grade often decreased soon after romiplostim discontinuation. In the prospective study, reticulin grade during romiplostim treatment remained within the normal range for all patients and was increased in only 1 of 6 patients with pretreatment and on-treatment bone marrow results. This report suggests that romiplostim produces reversible, dose-dependent bone marrow changes in rats and produces modest increases in bone marrow reticulin in some ITP patients that decrease when therapy is discontinued. These studies were registered at www.clinicaltrials.gov as

show abstract

“…The use of specific stains in addition to hematoxylin and eosin is not essential to evaluate fibrosis in rat bone marrow because of the distinctive morphologic presentation. [24][25][26] …”

Section: Animal Studymentioning

confidence: 99%

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

Kuter

Mufti

Bain

et al. 2009

Blood

166

132

View full text Add to dashboard Cite

show abstract

“…The focus of this article will be evaluation of the bone marrow with the objectives of reviewing of some concepts regarding the bone marrow structure and function and review of qualitative and quantitative bone marrow evaluation methods. A review of various lesions of the bone marrow in laboratory rats, mice and dogs will be presented in a subsequent discussion (Travlos, 2006).…”

Section: Introductionmentioning

confidence: 99%

Normal Structure, Function, and Histology of the Bone Marrow

2006

Self Cite

View full text Add to dashboard Cite

While a complete blood count provides information regarding possible treatment-related effects reflected in the peripheral blood, morphological evaluation of bone marrow cytology and paraffin sections provides information about bone marrow tissue architecture that otherwise would be missed by examination of peripheral blood alone. In decalcified, paraffin-embedded, hematoxylin and eosin (H&E)-stained sections of bone marrow, the more mature stages of the erythroid and myeloid cells, adipocytes, mast cells, and megakaryocytes can be identified, but lymphoid cells as well as immature progenitor cells can not be reliably identified. The quality of the marrow sections is governed by numerous variables related to specimen collection and processing and must be considered. In addition to discussing normal structure, function, and histology of bone marrow, methods for preparation and evaluation of bone marrow are presented.

show abstract

“…In addition, similar results were found in the femur of sensitized recipients, this further confirmed that bone marrow environment is capable of eliciting memory immune responses to eliminate sensitized donor cells similar to hematopoietic and lymphoid organs. 25 The mechanism of marrow graft rejection in sensitized recipients has not been clearly defined. We evaluated the cytotoxicity of sensitization against donor BMCs by CDC, CTL and ADCC tests, and found that the cytotoxic index for sensitized samples were much higher than that for nonsensitized samples ( Figure 5).…”

Section: Discussionmentioning

confidence: 99%